Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children.
BACKGROUND
Gastrointestinal carcinomas in childhood are rare and frequently present at an advanced stage. Besides lymphatic and distant organ metastasis, peritoneal carcinomatosis may be detected and has a poor prognosis. In addition to surgery and intravenous chemotherapy, hyperthermic intraperitoneal chemoperfusion (HIPEC) may be an option for selected patients. Our aim was to demonstrate the feasibility of the method and to discuss possible indications.


METHODS
After treating a series of adult patients, HIPEC for peritoneal carcinomatosis from a signet cell carcinoma of the colon was performed intraoperatively in a 12-year-old boy. We gave mitomycin C at a dose of 30 mg/m2 over 90 minutes at maximum temperature of 41.2 degrees C. We performed intraoperative drug level monitoring and daily postoperative liver and kidney function tests and differential blood counts.


RESULTS
Hyperthermic intraperitoneal chemoperfusion was performed according to protocol without complications. Perfusate and venous drug levels were similar to those in an adult case. The patient had an uneventful recovery, and serum chemistry and blood count returned to normal after a week. The boy lived for 36 months after initial presentation. Sixteen months after HIPEC, still with excellent quality of life, an elevated carcinoembryonic antigen (CEA) indicated recurrence. Thirty months after HIPEC, he died of progressive recurrent disease.


CONCLUSIONS
Hyperthermic intraperitoneal chemoperfusion as performed in adults may be beneficial to children with peritoneal carcinomatosis and merits further study.
Reingruber
Bertram
B
Division of Pediatric Surgery, Department of Surgery, Friedrich-Alexander-University, 91054 Erlangen, Germany. bertram.reingruber@chir.imed.uni-erlangen.de
Boettcher
M I
MI
Klein
P
P
Hohenberger
W
W
Pelz
J O W
JO
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D010478:Chemotherapy, Cancer, Regional Perfusion; D002648:Child; D003110:Colonic Neoplasms / Q000473:pathology / Q000601:surgery; D006801:Humans; D006979:Hyperthermia, Induced; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary*
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin